article · Scandinavian Journal of Infectious Diseases
On July 24, 2026, Oxford reported administering ChAdOx1 BDBV to the first participant in BD-Ebov, the first Phase I trial of a vaccine designed specifically against Bundibugyo virus. This single-ce...
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1080/23744235.2026.2717159
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.